An Abstract of the Dissertation Of

Total Page:16

File Type:pdf, Size:1020Kb

An Abstract of the Dissertation Of AN ABSTRACT OF THE DISSERTATION OF Emerson C. Christie for the degree of Doctor of Philosophy in Toxicology presented on March 11, 2021. Title: Per- and Polyfluoroalkyl Substances (PFAS): Protein Binding and Partitioning and Sorption in Light Non-Aqueous Phase Liquids Abstract approved: ______________________________________________________ Jennifer A. Field Per- and polyfluoroalkyl substances (PFAS) are anthropogenic surfactants that have recently been identified as persistent organic pollutants. These so called “Forever Chemicals” have been detected in drinking waters, ground waters, soils, and consumer and industrial products globally; with environmental impacts stretching into the artic, far from known PFAS sources. The increase in awareness regarding PFAS distribution in the environment has generated interest into how PFAS interact with humans, what PFAS specific properties may be involved, and what additional environmental compartments may they be found in. In Chapter 2 we discuss the use of molecular dynamics (MD) modeling to screen for protein – PFAS binding affinity to inform experimental measurements of binding affinity via equilibrium dialysis (Eq D). The equilibrium dissociation constants (KD) of six perfluoroalkyl carboxylates (PFCAs) and three perfluoroalkyl sulfonates (PFSAs) to liver and intestinal fatty acid binding proteins (L- and I-FABPs) and peroxisome proliferator activated nuclear receptors (PPAR-α, - δ and - γ) were determined via liquid chromatography mass spectrometry. The MD models were found to predict relative and not absolute binding for all protein – PFAS combinations. This research was the first to identify sub micromolar binding between short chain PFAS (6 or less carbons) and PPAR-α and δ, which may have implications for the assumed safety of shorter chain PFAS due to rapid clearance. Chain length dependent binding was observed for L- FABP but not observed for PPAR proteins which means that for these proteins binding affinity cannot be inferred by PFAS chain length. Additionally, a comparison was made between KDs derived from EqD and other in-vitro approaches, using these experimental results and results from literature. It was discovered that KDs derived from EqD were lower (i.e. higher binding affinity) than other in-vitro approaches which has implications for comparisons between methodologies and raises an important question regarding which KDs should be considered most relevant in-vivo. Research discussed in Chapter 3 surrounds the development of an extraction and analytical method to quantify PFAS in environmental non-aqueous phase liquids (NAPL). As mentioned above, PFAS are used in industrial products and one common group of industrial products that have been identified as the root cause for environmental PFAS contamination at U.S. military sites are aqueous film forming foams (AFFF). AFFF are complex mixtures known to contain high concentrations of many surfactants including PFAS. At U.S. military sites it is also common to encounter NAPL in the subsurface. Co-disposal of PFAS (AFFF) with NAPL has happened historically through intentional use (e.g. firefighting) or unintentionally at waste sites. In order to quantify PFAS within NAPL, a liquid-liquid extraction method was developed that could successfully extract anionic, cationic, and zwitterionic PFAS. This research discovered the presence of PFAS in recovered NAPL at microgram per liter concentrations at non-source zone sites. Concentrations of PFAS in NAPL are likely much higher at source zone sites and could have implications for NAPL remediation. Chapter 4 discusses the partitioning and interfacial adsorption of PFAS into NAPL at environmentally relevant concentrations (i.e. nano – microgram per liter). Given the discovery of low microgram per liter concentrations of PFAS in recovered NAPL discussed in Chapter 3, it is relevant to investigate what partitioning and sorption processes are occurring at these concentrations. Current research in this area has focused on the NAPL – water interface and has done so at high concentrations, milli – gram per liter. Here we performed batch equilibrium experiments at low concentrations (2,000 – 100,000 ng/L) between jet fuel A (NAPL) and synthetic freshwater. Single point partition coefficients (Kn) were calculated for PFAS of carbon chain length 8-14 across the concentration range. Values for Kn decreased with increasing PFAS concentration indicating non-ideal partitioning, which become more evident with increasing chain length. Partitioning into jet fuel A was not observed for PFAS below eight carbons. Interfacial sorption (Knw) was estimated by mass difference and found to be orders of magnitude higher than previously reported literature values. ©Copyright by Emerson C. Christie March 11, 2021 All Rights Reserved Per- and Polyfluoroalkyl Substances (PFAS): Protein Binding and Partitioning and Sorption in Light Non-Aqueous Phase Liquids by Emerson C. Christie A DISSERTATION submitted to Oregon State University in partial fulfillment of the requirements for the degree of Doctor of Philosophy Presented March 11, 2021 Commencement June 2021 Doctor of Philosophy dissertation of Emerson C. Christie presented on March 11, 2021 APPROVED: Major Professor, representing Toxicology Head of the Department of Environmental and Molecular Toxicology Dean of the Graduate School I understand that my dissertation will become part of the permanent collection of Oregon State University libraries. My signature below authorizes release of my dissertation to any reader upon request. Emerson C. Christie, Author ACKNOWLEDGEMENTS I would like to thank my wife, Brittany Poirson, for her support during the intense ride that was finishing graduate school while parenting, buying a house, moving, and a double career change, all during a pandemic. My son, Obadiah, for mandating work life balance and providing an unconditional bright smile during acutely stressful times. My soon to be born daughter, Marigold, guiding me towards the world ahead. My parents, Kevin and Libby Christie, for continuous support throughout my life. My sister, Kara Trella, for teaching me creative vision. My brother, Jack Anson, for teaching me the strength of spirit. Thank you to Dr. Alix Robel, Dr. Justin Rewerts, and Dr. Serhan Mermer for teaching me LC MS/MS and enough about lab and instrument health to keep things moving forward. Thank you to my Field Lab members who helped me develop ideas, accomplish objectives, and keep instruments running. Thank you to the many collaborators who worked very hard on the research here-in. Thank you to my committee Dr. Markus Kleber, Dr. Jeffrey Jenkins, Dr. Charles Schaefer, and Dr. Ramesh Sagili; for all their advice in making this research possible. And a big thank you to my adviser Dr. Jennifer Field for obviously seeing something in me, sharing her expertise, and guiding me on this quest. CONTRIBUTION OF AUTHORS In Chapter 2, Manoochehr Khazaee performed equilibrium dialysis experiments and contributed to manuscript write-up and edits. Weixiao Cheng performed molecular modeling and contributed to manuscript write-up and edits. Dr. Mandy Michalsen, Dr. Jennifer Field, and Dr. Carla Ng provided expertise in experimental design and manuscript edits. In Chapter 3, Dr. Bill Diguiseppi provided expertise in light non-aqueous phase liquids and manuscript edits. Dr. Konstantinos Kosterelos facilitated the collection of field samples and provided manuscript edits, and Dr. Jennifer A. Field provided experimental design expertise and manuscript edits. In Chapter 4, Dr. Charles Schaefer provided PFAS interfacial modeling expertise and experimental design expertise. Dr. Konstantinos Kostarelos LNAPL and partitioning expertise. Dr. Jennifer A. Field provided experimental design expertise and manuscript edits. TABLE OF CONTENTS Page Chapter 1- Introduction.....…………………………………………………………… 1 1.1 Per and Polyfluoroalkyl Substances ………...…………………………………… 1 1.2 PFAS – Protein Interactions……………………………………………………… 2 1.3 PFAS – NAPL Connection.....…………………………………………………… 3 1.4 Methods to Analyze PFAS in NAPL......………………………………………… 4 1.5 PFAS – NAPL Partitioning..…...………………………………………………… 4 1.6 PFAS – NAPL Interfacial Sorption..…………..………………………………… 5 1.7 Summary of Research Performed…...…………………………………………… 6 1.8 References……….......…………………………………………………………… 7 Chapter 2 - Perfluoroalkyl acid binding with peroxisome proliferator-activated receptors , , and and fatty acid binding proteins by equilibrium dialysis with a comparison of methods.....…………………………………………………………...13 2.1 Abstract ….………………………………………………………………………14 2.2 Introduction ………...……………………………………………………………15 2.3 Materials and Methods ..…………………………………………………………17 2.4 Results and Discussion .…………………………………………………………12 2.5 Conclusion ………………………………………………………………………28 . 2.6 Acknowledgements …...…………………………………………………………29 2.7 References ……………………………………………………………………….30 Chapter 3 - Per and Polyfluorinated Alkyl Substances in Nonaqueous Phase Liquids……………………………………………………………………………….48 3.1 Abstract ….………………………………………………………………………49 3.2 Introduction ………...……………………………………………………………50 TABLE OF CONTENTS (Continued) Page 3.3 Experimental ………….…………………………………………………………52 3.4 Results and Discussion…………………………………………………………..57 3.5 Implications ……..……………………………………………………………….59 . 3.6 Acknowledgements …...…………………………………………………………60 3.7 References …………………………………………………………………….…60 Chapter 4 - Interfacial uptake and partitioning of per and polyfluorinated alkyl substances in Jet Fuel A at environmental concentrations …..………………………65
Recommended publications
  • Us 2018 / 0296525 A1
    UN US 20180296525A1 ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2018/ 0296525 A1 ROIZMAN et al. ( 43 ) Pub . Date: Oct. 18 , 2018 ( 54 ) TREATMENT OF AGE - RELATED MACULAR A61K 38 /1709 ( 2013 .01 ) ; A61K 38 / 1866 DEGENERATION AND OTHER EYE (2013 . 01 ) ; A61K 31/ 40 ( 2013 .01 ) DISEASES WITH ONE OR MORE THERAPEUTIC AGENTS (71 ) Applicant: MacRegen , Inc ., San Jose , CA (US ) (57 ) ABSTRACT ( 72 ) Inventors : Keith ROIZMAN , San Jose , CA (US ) ; The present disclosure provides therapeutic agents for the Martin RUDOLF , Luebeck (DE ) treatment of age - related macular degeneration ( AMD ) and other eye disorders. One or more therapeutic agents can be (21 ) Appl. No .: 15 /910 , 992 used to treat any stages ( including the early , intermediate ( 22 ) Filed : Mar. 2 , 2018 and advance stages ) of AMD , and any phenotypes of AMD , including geographic atrophy ( including non -central GA and Related U . S . Application Data central GA ) and neovascularization ( including types 1 , 2 and 3 NV ) . In certain embodiments , an anti - dyslipidemic agent ( 60 ) Provisional application No . 62/ 467 ,073 , filed on Mar . ( e . g . , an apolipoprotein mimetic and / or a statin ) is used 3 , 2017 . alone to treat or slow the progression of atrophic AMD Publication Classification ( including early AMD and intermediate AMD ) , and / or to (51 ) Int. CI. prevent or delay the onset of AMD , advanced AMD and /or A61K 31/ 366 ( 2006 . 01 ) neovascular AMD . In further embodiments , two or more A61P 27 /02 ( 2006 .01 ) therapeutic agents ( e . g ., any combinations of an anti - dys A61K 9 / 00 ( 2006 . 01 ) lipidemic agent, an antioxidant, an anti- inflammatory agent, A61K 31 / 40 ( 2006 .01 ) a complement inhibitor, a neuroprotector and an anti - angio A61K 45 / 06 ( 2006 .01 ) genic agent ) that target multiple underlying factors of AMD A61K 38 / 17 ( 2006 .01 ) ( e .
    [Show full text]
  • Integrative and Systemic Approaches for Evaluating Pparβ/Δ (PPARD)
    Integrative and systemic approaches for evaluating PPAR β/δ (PPARD) function Greta MP Giordano Attianese and Béatrice Desvergne Center for Integrative Genomics, University of Lausanne, Switzerland Footnotes: Corresponding author, BD: [email protected] Competing interests: The authors declare no competing financial interests Author contributions: Both authors have been involved in drafting the manuscript and revising it critically. Received December 5, 2014; Accepted March 9, 2015; Published April 27, 2015 Copyright © 2015 Giordano Attianese and Desvergne. This is an open-access article distributed under the terms of the Creative Commons Non-Commercial Attribution License, which permits unrestricted non-commercial use distribution and reproduction in any medium, provided the original work is properly cited. Abbreviations: αMyHC, α-Myosin Heavy Chain; BCL6, B-cell lymphoma 6 protein; BAT, Brown adipose tissue; ChIP, Chromatin Immunoprecipitation; CHD, Coronary heart disease; DBD, DNA-binding domain; FAO, Fatty Acid Oxidation; FA, Fatty Acid; GSIS, Glucose-stimulated insulin secretion; HSC, Hematopoietic Stem cells; H&E, Hematoxylin and Eosin; HDAC1, Histone deacetylase 1; LBD, Ligand binding domain; MCP1, Monocyte chemotactic protein 1; NFkB, Nuclear factor kappa-light-chain- enhancer of activated B cells; NR, Nuclear Receptor; NCoR1, Nuclear receptor co-repressor 1; PPARs, Peroxisome proliferator- activated receptors; PPRE, PPAR-responsive element; RER, Respiratory Exchange Ratio; RA, Retinoic Acid; RXR, Retinoid X receptor; SMRT, Silencing mediator of retinoic acid and thyroid hormone receptors; SNPs, Single Nucleotide Polymorphisms; SUMO, Small Ubiquitin-like Modifier; TZDs, Thiazolidinediones; TR, Thyroid hormone receptor; TG, Triglycerides; VLDL, Very large density lipoprotein; WOSCOPS, West of Scotland Coronary Prevention Study; WAT, White adipose tissue. Citation: Giordano Attianese G and Desvergne B (2015) Integrative and systemic approaches for evaluating PPAR β/δ (PPARD) function.
    [Show full text]
  • Development of Novel Synthetic Routes to the Epoxyketooctadecanoic Acids
    DEVELOPMENT OF NOVEL SYNTHETIC ROUTES TO THE EPOXYKETOOCTADECANOIC ACIDS (EKODES) AND THEIR BIOLOGICAL EVALUATION AS ACTIVATORS OF THE PPAR FAMILY OF NUCLEAR RECEPTORS By ROOZBEH ESKANDARI Submitted in partial fulfillment of the requirements for The Degree of Doctor of Philosophy Thesis Advisor: Gregory P. Tochtrop, Ph.D. Department of Chemistry CASE WESTERN RESERVE UNIVERSITY January, 2016 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of ROOZBEH ESKANDARI Candidate for the Ph.D degree *. (signed) Anthony J. Pearson, PhD (Chair of the committee) Gregory P. Tochtrop, PhD (Advisor) Michael G. Zagorski, PhD Blanton S. Tolbert, PhD Witold K. Surewicz, PhD (Department of Physiology and Biophysics) (date) 14th July, 2015 *We also certify that written approval has been obtained for any proprietary material contained therein. I dedicate this work to my sister Table of Contents Table of Contents ........................................................................................................................ i List of Tables .............................................................................................................................. vi List of Figures ........................................................................................................................... vii List of Schemes .......................................................................................................................... ix Acknowledgements ..................................................................................................................
    [Show full text]
  • Cellular and Pharmacological Selectivity of the Peroxisome Proliferator-Activated Receptor-ß/Δ Antagonist GSK3787
    0026-895X/10/7803-419–430 MOLECULAR PHARMACOLOGY Vol. 78, No. 3 U.S. Government work not protected by U.S. copyright 65508/3613101 Mol Pharmacol 78:419–430, 2010 Printed in U.S.A. Cellular and Pharmacological Selectivity of the Peroxisome Proliferator-Activated Receptor-␤/␦ Antagonist GSK3787□S Prajakta S. Palkar, Michael G. Borland, Simone Naruhn, Christina H. Ferry, Christina Lee, Ugir H. Sk, Arun K. Sharma, Shantu Amin, Iain A. Murray, Cherie R. Anderson, Gary H. Perdew, Frank J. Gonzalez, Rolf Mu¨ ller, and Jeffrey M. Peters Department of Veterinary and Biomedical Sciences and the Center for Molecular Toxicology and Carcinogenesis, the Pennsylvania State University, University Park, Pennsylvania (P.S.P., M.G.B., C.H.F., C.L., I.A.M., C.R.A., G.H.P., J.M.P.); Institute of Molecular Biology and Tumor Research, Philipps University, Marburg, Germany (S.N., R.M.); Department of Pharmacology, Penn State Hershey Cancer Institute, the Pennsylvania State University, Milton S. Hershey Medical Center, Hershey, Pennsylvania (A.K.S., U.H.S., S.A.); and Laboratory of Metabolism, National Cancer Institute, Bethesda, Maryland (F.J. G.) Received April 9, 2010; accepted June 1, 2010 ABSTRACT The availability of high-affinity agonists for peroxisome prolifera- PPAR␣ activity. Time-resolved fluorescence resonance energy tor-activated receptor-␤/␦ (PPAR␤/␦) has led to significant ad- transfer assays confirmed the ability of GSK3787 to modulate the vances in our understanding of the functional role of PPAR␤/␦.In association of both PPAR␤/␦ and PPAR␥ coregulator peptides in this study, a new PPAR␤/␦ antagonist, 4-chloro-N-(2-{[5-tri- response to ligand activation, consistent with reporter assays.
    [Show full text]
  • A2E Induces the Transactivation of Rars, Ppars and Rxrs and Its Effects Are Counteracted by Norbixin in Retinal Pigment Epithelium Cells in Vitro
    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.30.016071; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. A2E induces the transactivation of RARs, PPARs and RXRs and its effects are counteracted by norbixin in retinal pigment epithelium cells in vitro Valérie Fontaine1 *, Mylène Fournié1, Elodie Monteiro1, Thinhinane Boumedine1, Christine Balducci2, Louis Guibout2, Mathilde Latil2, Pierre J. Dilda2, José-Alain Sahel1,3,4, Stanislas Veillet2, René Lafont2, Serge Camelo2 1 Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 Rue Moreau, F-75012 Paris, France 2 Biophytis, Sorbonne Université, BC9, 4 place Jussieu, 75005 Paris, France 3 CHNO des Quinze-Vingts, DHU Sight Restore, INSERM-DGOS CIC 1423, 28 rue de Charenton, F- 75012, Paris, France 4 Department of Ophthalmology, The University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA *Corresponding author: Valérie Fontaine Email: [email protected] Running Title: Norbixin modulates NRs activation by A2E in RPE cells Keywords: N-retinylidene-N-retinylethanolamine (A2E), angiogenesis, apoptosis, inflammation, norbixin, nuclear receptor (NR), peroxisome proliferator-activated receptor (PPAR), retinoic acid receptor (RAR), retinal pigment epithelium (RPE), retinoic X receptor (RXR) ABSTRACT transactivation induced by A2E. Norbixin also N-retinylidene-N-retinylethanolamine (A2E) inhibits PPAR-g transactivation induced by its plays a central role in age-related macular high affinity ligand troglitazone. degeneration (AMD) by inducing apoptosis, Photoprotection of RPE cells by norbixin angiogenesis and inflammation. It has been correlates with maintained levels of the proposed that A2E effects are mediated at least antiapoptotic B-cell lymphoma 2 (Bcl2) partly via the retinoic acid receptor (RAR)-a.
    [Show full text]
  • The Role of Peroxisome Proliferator-Activated Receptor
    The Pennsylvania State University The Graduate School The Huck Institutes for Life Sciences THE ROLE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR β/δ IN VIRAL PROTEIN-INDUCED LIVER PATHOGENESIS A Dissertation in Molecular Medicine by Gayathri Balandaram © 2015 Gayathri Balandaram Submitted in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy December 2015 The dissertation of Gayathri Balandaram was reviewed and approved* by the following: Jeffrey M. Peters Distinguished Professor of Molecular Toxicology and Carcinogenesis Dissertation Advisor Chair of Committee Gary H. Perdew John T. and Paige S. Smith Professor in Agricultural Sciences Connie J. Rogers Assistant Professor and Occupant of the Broadhurst Career Development Professorship for the Study of Health Promotion and Disease Prevention Andrew Patterson Associate Professor of Molecular Toxicology Adam B. Glick Associate Professor of Veterinary and Biomedical Sciences Chair, Molecular Medicine Program Associate Chair, Molecular Cellular and Integrative Biosciences *Signatures are on file in the Graduate School ii ABSTRACT PPARβ/δ has an established role in attenuating preneoplastic conditions in the liver such as inflammation, steatosis, proliferation and oxidative stress pointing to a chemopreventive role for this nuclear receptor in the liver. However, not much is known about its part in orchestrating the progression of hepatocellular carcinoma. The present study examined the potential of this nuclear receptor in delaying the progression of chronic hepatocellular injury-induced liver cancer. In hepatitis B virus (HBV) transgenic mice, which develop progressive inflammation and cellular injury at the early stages (2-3 months of age), followed by hyperplasia, neoplasia and eventually hepatocellular carcinoma at later stages (12-18 months of age), long-term ligand activation (8 months) with PPARβ/δ ligand (GW0742), displayed a significant attenuation in tumor multiplicity and the average number of liver foci, which was not observed in HBV mice not treated with GW0742.
    [Show full text]
  • Investigation of Pparβ/Δ Within Human Dental Pulp Cells: a Preliminary in Vitro Study
    Hindawi PPAR Research Volume 2021, Article ID 8854921, 10 pages https://doi.org/10.1155/2021/8854921 Research Article Investigation of PPARβ/δ within Human Dental Pulp Cells: A Preliminary In Vitro Study Caroline L. de Lima ,1,2 Bruna R. Amorim ,1 Carine Royer ,2 Augusto P. Resende ,1 Maria F. Borin ,2 Francisco A. R. Neves ,2 and Ana Carolina Acevedo 1 1Laboratory of Oral Histopathology, Faculty of Health Sciences, University of Brasilia, University Campus Darcy Ribeiro, Brasília, Brazil 2Laboratory of Molecular Pharmacology, Faculty of Health Sciences, University of Brasilia, University Campus Darcy Ribeiro, Brasília, Brazil Correspondence should be addressed to Francisco A. R. Neves; [email protected] and Ana Carolina Acevedo; [email protected] Received 30 July 2020; Revised 15 January 2021; Accepted 17 February 2021; Published 19 March 2021 Academic Editor: Ravinder K. Kaundal Copyright © 2021 Caroline L. de Lima et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Controlling the inflammatory response to restore tissue homeostasis is a crucial step to maintain tooth vitality after pathogen removal from caries-affected dental tissues. The nuclear peroxisome proliferator-activated receptor beta/delta (PPARβ/δ)isa ligand-activated transcription factor with emerging anti-inflammatory roles in many cells and tissues. However, its expression and functions are poorly understood in human dental pulp cells (hDPCs). Thus, this study evaluated PPARβ/δ expression and assessed the anti-inflammatory effects evoked by activation of PPARβ/δ in lipopolysaccharide- (LPS-) induced hDPCs.
    [Show full text]
  • Structural Insights Into Human Peroxisome Proliferator Activated Receptor Delta (PPAR-Delta) Selective Ligand Binding
    Structural Insights into Human Peroxisome Proliferator Activated Receptor Delta (PPAR-Delta) Selective Ligand Binding Fernanda A. H. Batista1., Daniela B. B. Trivella1.¤, Amanda Bernardes1, Joyce Gratieri1, Paulo S. L. Oliveira2, Ana Carolina M. Figueira2, Paul Webb3, Igor Polikarpov1* 1 Instituto de Fı´sica de Sa˜o Carlos, Universidade de Sa˜o Paulo, Sa˜o Carlos, Sao Paulo, Brazil, 2 Laborato´rio Nacional de Biocieˆncias, Centro Nacional de Pesquisas em Energia e Materiais (CNPEM/ABTLUS) Laborato´rio Nacional de Biociencias (LNBio), Campinas, Sao Paulo, Brazil, 3 Diabetes Center and Cancer Research Unit, The Methodist Hospital Research Institute, Houston, Texas, United States of America Abstract Peroxisome proliferator activated receptors (PPARs d, a and c) are closely related transcription factors that exert distinct effects on fatty acid and glucose metabolism, cardiac disease, inflammatory response and other processes. Several groups developed PPAR subtype specific modulators to trigger desirable effects of particular PPARs without harmful side effects associated with activation of other subtypes. Presently, however, many compounds that bind to one of the PPARs cross- react with others and rational strategies to obtain highly selective PPAR modulators are far from clear. GW0742 is a synthetic ligand that binds PPARd more than 300-fold more tightly than PPARa or PPARc but the structural basis of PPARd:GW0742 interactions and reasons for strong selectivity are not clear. Here we report the crystal structure of the PPARd:GW0742 complex. Comparisons of the PPARd:GW0742 complex with published structures of PPARs in complex with a and c selective agonists and pan agonists suggests that two residues (Val312 and Ile328) in the buried hormone binding pocket play special roles in PPARd selective binding and experimental and computational analysis of effects of mutations in these residues confirms this and suggests that bulky substituents that line the PPARa and c ligand binding pockets as structural barriers for GW0742 binding.
    [Show full text]
  • Small-Molecule Modulation of Ppars for the Treatment of Prevalent Vascular Retinal Diseases
    International Journal of Molecular Sciences Review Small-Molecule Modulation of PPARs for the Treatment of Prevalent Vascular Retinal Diseases Xiaozheng Dou 1 and Adam S. Duerfeldt 2,* 1 Department of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, IN 46656, USA; [email protected] 2 Department of Chemistry & Biochemistry, University of Oklahoma, Norman, OK 73019, USA * Correspondence: [email protected]; Tel.: +405-325-2232 Received: 20 October 2020; Accepted: 2 December 2020; Published: 4 December 2020 Abstract: Vascular-related retinal diseases dramatically impact quality of life and create a substantial burden on the healthcare system. Age-related macular degeneration, diabetic retinopathy,and retinopathy of prematurity are leading causes of irreversible blindness. In recent years, the scientific community has made great progress in understanding the pathology of these diseases and recent discoveries have identified promising new treatment strategies. Specifically, compelling biochemical and clinical evidence is arising that small-molecule modulation of peroxisome proliferator-activated receptors (PPARs) represents a promising approach to simultaneously address many of the pathological drivers of these vascular-related retinal diseases. This has excited academic and pharmaceutical researchers towards developing new and potent PPAR ligands. This review highlights recent developments in PPAR ligand discovery and discusses the downstream effects of targeting PPARs as a therapeutic approach to treating retinal vascular diseases.
    [Show full text]
  • Amorfrutins Are Potent Antidiabetic Dietary Natural Products
    Amorfrutins are potent antidiabetic SEE COMMENTARY dietary natural products Christopher Weidnera,b, Jens C. de Grootc, Aman Prasadd, Anja Freiwalda, Claudia Quedenaua, Magdalena Kliema, Annabell Witzkea, Vitam Kodeljaa, Chung-Ting Hana, Sascha Giegolde, Matthias Baumanne, Bert Kleble, Karsten Siemsf, Lutz Müller-Kuhrtf, Annette Schürmanng, Rita Schülerg, Andreas F. H. Pfeifferg, Frank C. Schroederd, Konrad Büssowc, and Sascha Sauera,1 aOtto Warburg Laboratory, Max Planck Institute for Molecular Genetics, Ihnestrasse 63-73, 14195 Berlin, Germany; bDepartment of Biology, Chemistry, and Pharmacy, Free University of Berlin, Takustrasse 3, 14195 Berlin, Germany; cDivision of Structural Biology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7, 38124 Braunschweig, Germany; dDepartment of Chemistry and Chemical Biology and Boyce Thompson Institute, Cornell University, Ithaca, NY 14853; eLead Discovery Center GmbH, Emil-Figge-Strasse 76a, 44227 Dortmund, Germany; fAnalytiCon Discovery GmbH, Hermannswerder Haus 17, 14473 Potsdam, Germany; and gGerman Institute of Human Nutrition, Arthur-Scheunert-Allee 114-116, 14558 Nuthetal, Germany Edited by Jerrold Meinwald, Cornell University, Ithaca, NY, and approved February 22, 2012 (received for review October 17, 2011) Given worldwide increases in the incidence of obesity and type 2 of PPARs may promote specific gene expression profiles that diabetes, new strategies for preventing and treating metabolic result in more favorable outcomes. The use of selective PPARγ diseases are needed. The nuclear receptor PPARγ (peroxisome pro- modulators (SPPARγMs) (9–11) as well as inhibition of phos- liferator-activated receptor gamma) plays a central role in lipid and phorylation of serine 273 of PPARγ by small molecules are two glucose metabolism; however, current PPARγ-targeting drugs are recently proposed approaches for improving insulin sensitivity characterized by undesirable side effects.
    [Show full text]
  • Peroxisome Proliferator Activated Receptors
    www.aladdin-e.com Address:800 S Wineville Avenue, Ontario, CA 91761,USA Website:www.aladdin-e.com Email USA: [email protected] Email EU: [email protected] Email Asia Pacific: [email protected] Peroxisome proliferator activated receptors Peroxisome proliferator activated receptors tissues during development especially in the (PPARs) are members of the nuclear hormone adult rat digestive tract where a high rate of cell receptor superfamily of ligand-activated renewal and differentiation is required. PPARγ is transcription factors that are related to retinoid, highly expressed in adipose tissue and is a key steroid and thyroid hormone receptors. PPARs transcription factor involved in the terminal play an important role in many cellular functions differentiation of white and brown adipose tissue. including lipid metabolism, cell proliferation, There is evidence that both PPARα and PPARγ differentiation, adipogenesis and inflammatory could interfere with atherogenesis, in part by signalling. PPARs have been found to interact exerting an anti-inflammatory activity. with a number of endogenous lipids and drugs for the treatment of human metabolic diseases. PPARs regulate gene expression by heterodimeric partnering with retinoid X receptors There are three distinct PPAR subtypes which (RXR) and subsequent binding to specific are the products of different genes and are response elements (PPREs) in the promoter commonly designated PPARα [NR1C1], PPARδ regions of target genes. Structurally distinct (also known as PPARβ and NUC1) [NR1C2] and PPREs are recognized by PPARα, δ and γ. PPARγ [NR1C3]. Each receptor shows a PPAR-RXR heterodimers can also be activated differential pattern of tissue expression and is by ligand binding to either receptor partner activated by structurally diverse compounds independently.
    [Show full text]
  • A Peroxisome Proliferator-Activated Receptor-δ Agonist Provides
    Neuroscience 240 (2013) 191–203 A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-d AGONIST PROVIDES NEUROPROTECTION IN THE 1-METHYL-4-PHENYL-1,2,3, 6-TETRAHYDROPYRIDINE MODEL OF PARKINSON’S DISEASE H. L. MARTIN, a R. B. MOUNSEY, a K. SATHE, a INTRODUCTION S. MUSTAFA, a M. C. NELSON, b R. M. EVANS b AND P. TEISMANN a* Parkinson’s disease (PD) is a common neurodegenera- a Institute of Medical Sciences, University of Aberdeen, tive disease (Dauer and Przedborski, 2003). Its primary Aberdeen, United Kingdom neuropathogical feature is the loss of dopaminergic b Gene Expression Laboratory, Salk Institute, La Jolla, CA, USA nigrostriatal neurons, which results in the disabling motor abnormalities that characterise PD: rigidity, bradykinesia, resting tremor and postural instability Abstract—Peroxisome proliferator-activated receptor (Dauer and Przedborski, 2003). The pathogenesis of PD (PPAR)-c and PPARa have shown neuroprotective effects is poorly understood, but amongst the processes in models of Parkinson’s disease (PD). The role of the third, implicated in the degeneration of the dopaminergic more ubiquitous isoform PPARd has not been fully explored. neurons is inflammation, as evidenced by the activated This study investigated the role of PPARd in PD using 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to model glial cells and the upregulation of pro-inflammatory the dopaminergic neurodegeneration of PD. In vitro admin- cytokines seen in both models of PD and PD patients istration of the PPARd antagonist GSK0660 (1 lM) increased (Czlonkowska et al., 1996; He´bert et al., 2003 McGeer the detrimental effect of 1-methyl-4-phenylpyridinium iodide et al., 1988; Mogi et al., 1994a,b).
    [Show full text]